<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84018">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01961349</url>
  </required_header>
  <id_info>
    <org_study_id>D0092C00002</org_study_id>
    <nct_id>NCT01961349</nct_id>
  </id_info>
  <brief_title>Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy</brief_title>
  <acronym>Kagami_SDS</acronym>
  <official_title>A Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Confirmatory Study to Assess Efficacy and Safety of the Moderate Sedation of ICI35,868 With and Without EES0000645/A on Gastrointestinal Endoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Johnson &amp; Johnson</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Japan: Pharmaceutical and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed as a multi-centre, randomised, parallel-group, placebo-controlled,
      phase III confirmatory study.  The study will be partially double-blinded: the comparison
      between Group 1 (placebo group) and Group 2 (ICI35,868 without EES0000645/A) will be carried
      out in double-blind, but the comparison between Group 1 (placebo group) and Group 3
      (ICI35,868 with EES0000645/A) will be carried out in single-blind.

      The efficacy and safety of ICI35,868 with and without EES0000645/A for the sedation to be
      moderate for a diagnostic gastrointestinal endoscopy and gastrointestinal endoscopic
      polypectomy will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Achievement of &quot;target sedation&quot; using MOAA/S score</measure>
    <time_frame>During procedure</time_frame>
    <safety_issue>No</safety_issue>
    <description>The target sedation is defined to be Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scores of 2 to 4 for ≥50% of all MOAA/S measurements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction (PSSI questionnaire)</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate subject satisfaction with sedation using Patient Satisfaction with Sedation Instrument (PSSI) questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory episodes</measure>
    <time_frame>5 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Decreased SpO2 (degree of saturation &lt;90% for ≥ 15 seconds)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group 1 (placebo group) is treated by Anaesthesiologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 2 (ICI35,868 without EES0000645/A) is treated by Anaesthesiologist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group 3 (ICI35,868 with EES0000645/A) is treated by Endoscopist</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intralipid</intervention_name>
    <description>Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICI35,868 (Diprivan)</intervention_name>
    <description>Treated by Anaesthesiologist</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICI35,868 (Diprivan) + EES0000645/A (SDS)</intervention_name>
    <description>Treated by Endoscopist with EES0000645/A(SDS)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Provision of written informed consent prior to any study-related procedures/examinations
        2.Aged 20 years and older 3.Subjects who are planned to undergo a non-emergent EGD or
        colonoscopy, including gastrointestinal endoscopic polypectomy that shall be completed
        within 1 hour (excluding the endoscopic submucosal dissection and ultrasonic endoscope,
        pernasal endoscope, etc.). Exclusion Criteria:

          1. involvement in the planning and/or conduct of the study (applies to both sponsor's
             employees and/or staffs at the study site)

          2. Subjects who underwent a endoscopic procedure under ICI35,868 (propofol)
             administration within 1 year.

          3. Participation in another clinical study with an investigational product within 4
             weeks prior to randomisation.

          4. Baseline (Visit 1) of blood oxygen saturation (SpO2)&lt;90% (room air)

          5. ASA III, IV, V and VI ; Subject with serious disease of cardiovascular, respiratory,
             renal, liver, pancreatic or endocrine function.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moriya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>October 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sedation, propofol, gastrointestinal endoscopy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
